Cordio Medical received an investment from Iron Nation, an impact fund ensuring the continuity of Israeli startups in the wake of the October 7th massacre.
The funds will assist the company in accelerating the journey toward FDA approval for its groundbreaking HearO platform, bringing Cordio Medical closer to enhancing the health of millions worldwide.
Cordio Medical’s cutting-edge voice analysis technology, HearO, is a medical-grade digital platform designed to assist patients with Congestive Heart Failure (CHF) and their caregivers. By simply recording voice samples in the HearO smartphone application, users can monitor their condition effectively.
The advanced Speech Processing Technology of HearO analyzes the patient’s voice to detect fluid build-up in the lungs, identifying condition deterioration up to 30 days before clinical symptoms appear. This early detection capability has the potential to significantly improve patient outcomes and quality of life, as CHF complications result in half a million deaths and incur $35 billion in costs annually in the US alone.
